U.S. Markets close in 1 hr 51 mins

RedHill Biopharma Ltd. (RDHL)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
4.7500-0.0600 (-1.25%)
As of 4:00PM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close4.8100
Bid4.7100 x 900
Ask4.7900 x 900
Day's Range4.6291 - 4.8682
52 Week Range4.4800 - 11.5200
Avg. Volume815,496
Market Cap221.92M
Beta (5Y Monthly)1.40
PE Ratio (TTM)N/A
EPS (TTM)-2.1350
Earnings DateMay 27, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est19.94
  • PR Newswire

    RedHill Biopharma Announces Settlement of Movantik® Patent Litigation with Aurobindo

    RedHill Biopharma Ltd. (Nasdaq: RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that RedHill Biopharma Inc., AstraZeneca AB and AstraZeneca Pharmaceuticals LP ("AstraZeneca") and Nektar Therapeutics have entered into a settlement and license agreement with Aurobindo Pharma USA, Inc. resolving their patent litigation in the U.S. in response to Aurobindo's Abbreviated New Drug Application ("ANDA") seeking approval by the US. Food and Drug Administration (

  • Zacks

    RedHill (RDHL) Down on Unsatisfactory Data From COVID-19 Study

    RedHill (RDHL) posts preliminary top-line data from a phase II/III study evaluating opaganib in hospitalized patients with severe COVID-19 pneumonia. Stocks falls as the study fails to achieve its goal.

  • Motley Fool

    Why RedHill Biopharma Stock Is Getting Crushed Today

    Shares of the specialty biopharmaceutical company RedHill Biopharma (NASDAQ: RDHL) are down by an eye-popping 33% as of 10:53 a.m. EDT Tuesday morning. Interestingly, the market appears to have anticipated this clinical failure, as evinced by RedHill's steady decline over the course of the past week. While opaganib's COVID-19 indication probably wasn't going to be a huge moneymaker for RedHill (analysts expected roughly $200 million to $300 million at the peak from this indication), this sizable market may have had enough juice to transform the company into a profitable operation perhaps as soon as next year.